Table 1.
Baseline and treatment characteristics of adult childhood cancer survivors
| Baseline Characteristics and Treatment Factors | Total Cohort N (%)/Median (Range; n=763 [100]) | Renal Tumor Survivors N (%)/Median (Range; n=85 [100]) | ||
|---|---|---|---|---|
| Sex (men) | 414 (54.3) | 45 (52.9) | ||
| Age at diagnosis (yr) | 7.3 (0.0–18.0) | 2.8 (0.0–15.0) | ||
| Age at follow-up (yr) | 26.9 (17.8–65.8) | 27.9 (17.9–49.0) | ||
| Follow-up time (yr) | 18.3 (5.0–58.2) | 24.4 (12.2–41.1) | ||
| Long-term survivors (>5 yr) | 438 (57.4) | — | ||
| Very long-term survivors (>20 yr) | 325 (42.6) | — | ||
| Diagnosis N (%) | ||||
| Acute lymphoblastic leukemia/T-NHL | 216 (28.3) | — | ||
| Acute myeloid leukemia | 26 (3.4) | — | ||
| B cell non-Hodgkin’s lymphoma | 68 (8.9) | — | ||
| Hodgkin’s lymphoma | 80 (10.5) | — | ||
| Bone tumor | 35 (4.6) | — | ||
| Renal tumor | 85 (11.1) | — | ||
| Neuroblastoma | 50 (6.6) | — | ||
| Langerhans cell histiocytosis | 14 (1.8) | — | ||
| Germ cell tumor | 18 (2.4) | — | ||
| Malignant mesenchymal tumor | 67 (8.8) | — | ||
| Brain tumor | 76 (9.9) | — | ||
| Other tumors | 28 (3.7) | — | ||
| Recurrence (≥1) | 91 (11.9) | 8 (9) | ||
| Treatment | N (%) | Median (Range) | N (%) | Median (Range) |
| Chemotherapy | TCD (mg/m2) | TCD (mg/m2) | ||
| Cisplatin | 51 (6.7) | 450 (18–900) | 1 (1.2) | 450 |
| Carboplatin | 16 (2.1) | 2050 (500–7150) | 0 | NA |
| Ifosfamide | 75 (9.8) | 18,000 (4–96,000) | 4 (4.7) | 36000 (30,000–36,000) |
| Cyclophosphamide | 305 (40.0) | 3500 (45–45,990) | 5 (5.9) | 5250 (250–7400) |
| Methotrexate | 319 (41.8) | 1 (1.2) | Unknown | |
| Intrathecal | 277 (36.3 | 108 (1–420) | — | |
| Intravenous | 236 (30.9) | 10,000 (45–198,000) | — | |
| Oral | 250 (32.7) | Unknown | — | |
| Radiotherapy | TCD (Gray) | TCD (Gray) | ||
| Abdominal radiotherapy | 47 (6.2) | 23 (10–40) | 29 (34) | 21 (15–30) |
| Total body irradiation | 26 (3.4) | 10 (6–20) | — | |
| Spinal irradiation | 23 (3.0) | 40 (21–44) | — | |
| Nephrectomy | 85 (11.3) | |||
| Renal replacement therapya | 3 (0.5) | |||
T-NHL, T cell non-Hodgkin’s lymphoma; TCD, total cumulative dose.
a
Renal replacement therapy includes dialysis and renal transplantation.